|Articles|May 29, 2013

NEW interchangeable single-use sterile connectors - for easy integration, flexibility

New genderless AseptiQuik? G Connectors from Colder Products Company make single-use sterile connections faster, easier and safer than ever before.

NEW interchangeable single-use sterile connectors – for easy integration, flexibility 

New genderless AseptiQuik® G Connectors from Colder Products Company make single-use sterile connections faster, easier and safer than ever before—even in non-sterile conditions. The genderless design eliminates separate male and female components, allowing any G series connectors to mate together.  This universal “G” mating simplifies systems integration and increases process flexibility for transferring valuable media.

The unique design of AseptiQuik G connectors minimizes the risk of operator error, reduces complexity, labor and inventory requirements. The new G series is available in a full range of interchangeable 1/4” to 3/4” flow solutions, in both gamma and high-temperature versions. Terminations include 1/4” hose barb, 1/2” hose barb, 3/4” hose barb and 3/4” sanitary.

The AseptiQuik family of connectors—in a full range of 1/8” to 1” flow configurations—provides unequalled ease of use and robust construction for reliable, repeatable performance without burdensome assembly aids, clamps or tube welding. AseptiQuik connectors are ideal for single-use bag and tubing assemblies, bioreactors, mixers, sampling and filling applications.  For applications where reliability and sterility are a must, Connect with Colder.

See how easy connections are with AseptiQuik® G —click here for video.

Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.